<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156401</url>
  </required_header>
  <id_info>
    <org_study_id>UMCM-2013EPI02</org_study_id>
    <nct_id>NCT02156401</nct_id>
  </id_info>
  <brief_title>VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE</brief_title>
  <acronym>VTEval</acronym>
  <official_title>VTEval Project - Three Observational, Prospective Cohort Studies Including Biobanking to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hochschule Fresenius</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siemens Corporation, Corporate Technology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eurofins</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT)&#xD;
      and pulmonary embolism (PE) is a life-threatening disease that is associated with&#xD;
      considerable morbidity and mortality. The incidence of VTE increases with age and it - as the&#xD;
      third most common cardiovascular disease after ischemic heart disease and stroke - represents&#xD;
      an important public health problem in industrialized countries with several aspects in need&#xD;
      to be addressed.&#xD;
&#xD;
      VTEval Project includes three long-term prospective observational studies to evaluate and&#xD;
      improve VTE diagnostics and management, treatment and outcome. The aims of the project&#xD;
      include a systematic assessment of VTE, i.e. disease status (symptoms, clinical and&#xD;
      subclinical aspects) and risk profiles (classic, psychosocial and environmental factors),&#xD;
      using a system-oriented approach. VTEval collects three large prospective cohorts of patients&#xD;
      with suspected and incident VTE consisting of individuals with a clinical suspicion of acute&#xD;
      PE, individuals with a clinical suspicion of acute DVT, and individuals with incidental&#xD;
      diagnosis of VTE).&#xD;
&#xD;
      The standardized and harmonized data acquisition of the study establishes a sustainable&#xD;
      resource for comprehensive research on VTE, thus providing the basis for both short- and&#xD;
      long-term analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Baseline</time_frame>
    <description>Overall mortality, consisting of:&#xD;
PE-related death&#xD;
All other causes of death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic venous thromboembolism</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
    <description>Composed by:&#xD;
PE-related death&#xD;
Development or recurrence of nonfatal PE&#xD;
Development or recurrence of DVT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic instability</measure>
    <time_frame>Baseline</time_frame>
    <description>Defined as at least one of the following:&#xD;
Cardiopulmonary resuscitation (CPR) or defibrillation&#xD;
Cardiogenic shock or need of catecholamine administration&#xD;
Systolic blood pressure &lt; 90mm Hg, or a pressure drop by more than 40mm Hg for &gt;15 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of mechanical ventilation</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to Intensive Care Unit (ICU)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of acute PE</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac dysfunction or heart failure</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumonia</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic and/or asymptomatic DVT</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non-major bleedings</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic of a previously unknown malignancy</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation of vena cava filter</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolytic treatment</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interventional treatment</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>Assessment at month 3/6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PE-related death</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development or recurrence of clinical symptomatic PE/DVT</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic DVT</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic venous insufficiency (CVI)</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-thrombotic Syndrome (PTS)</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of cardiac dysfunction or heart failure</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of pulmonary hypertension</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory dysfunction</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non-major bleedings</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic of a previously unknown malignancy</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net clinical outcome (NCO)</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O2 home treatment</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vasoactive drugs</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in Hospital due to VTE</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebrovascular event (MACCE)</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular event</measure>
    <time_frame>Assessment at month 3, 6 and 12; year 2-6 (Active follow-up)</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Venous Thromboembolism (VTE)</condition>
  <condition>Deep Vein Thrombosis (DVT)</condition>
  <condition>Pulmonary Embolism (PE)</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Suspect of Pulmonary Embolism (PE)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Suspect of Deep Vein Thrombosis (DVT)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Incidental Venous Thromboembolism (VTE)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Na-Citrated Plasma, EDTA-Plasma, DNA, RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals either with clinically suspected or incident diagnosis of VTE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and Informed written consent&#xD;
&#xD;
          -  Clinical condition:&#xD;
&#xD;
               -  Cohort 1: Clinical suspicion of acute PE (with or without DVT)&#xD;
&#xD;
               -  Cohort 2: Clinical suspicion of acute DVT (without symptomatic PE)&#xD;
&#xD;
               -  Cohort 3: Incidentally diagnosed VTE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp S Wild, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center of Johannes Gutenberg University Mainz, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philipp S Wild, MD, MSc</last_name>
    <phone>0049 6131 17 7163</phone>
    <email>philipp.wild@unimedizin-mainz.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center of the Johannes Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp S Wild, MD, MSc</last_name>
      <phone>00496131177163</phone>
      <email>philipp.wild@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Philipp S Wild, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stavros Konstantinides, MD, FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Philipp Wild, MD, MSc</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med. Philipp Wild, MSc</investigator_title>
  </responsible_party>
  <keyword>Venous thromboembolism</keyword>
  <keyword>Deep vein thrombosis</keyword>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Cohort study/epidemiology</keyword>
  <keyword>Outcome</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

